Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF516 antisense RNA 1 (ZNF516-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the ZNF516 gene. Like other antisense lncRNAs, it is presumed to regulate the expression of its neighboring sense gene (ZNF516) by acting at the RNA level, potentially affecting RNA stability or chromatin structure. While its precise functional and disease associations have not yet been defined in the literature, it is catalogued as an RNA gene without evidence of coding potential and without current therapeutic targeting or established links to pathological processes[6][7]. Notes: - ZNF516-AS1 is not a protein, receptor, enzyme, or classic drug target; it is a non-coding RNA. - There is no evidence in the presented results or in major gene databases that it is currently considered a therapeutic target or biomarker, nor are any drug interactions or safety concerns documented. - The closely related ZNF516 gene (not ZNF516-AS1) has been shown to function as a tumor suppressor via transcriptional repression in various cancers[1][4]; however, ZNF516-AS1’s roles remain uncharacterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNF516 antisense RNA 1 (ZNF516-AS1).